Cargando…

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children

The pediatric population receives the majority of vaccines globally, yet there is a paucity of studies on the transcriptional response induced by immunization in this special population. In this study, we performed a systems-level analysis of immune responses to the trivalent inactivated influenza v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kazmin, Dmitri, Clutterbuck, Elizabeth A., Napolitani, Giorgio, Wilkins, Amanda L., Tarlton, Andrea, Thompson, Amber J., Montomoli, Emmanuele, Lapini, Guilia, Bihari, Smiti, White, Rachel, Jones, Claire, Snape, Matthew D., Galal, Ushma, Yu, Ly-Mee, Rappuoli, Rino, Del Giudice, Giuseppe, Pollard, Andrew J., Pulendran, Bali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344887/ https://www.ncbi.nlm.nih.gov/pubmed/37443176 http://dx.doi.org/10.1038/s41541-023-00702-1

Ejemplares similares

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Editorial overview: Vaccines 2020
por: Pulendran, Bali, et al.
Publicado: (2020)

MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
por: Banzhoff, Angelika, et al.
Publicado: (2008)

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
por: Villa, Marco, et al.
Publicado: (2013)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus
por: Decaro, Nicola, et al.
Publicado: (2011)

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008)

H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix® vaccination
por: Ambati, Aditya, et al.
Publicado: (2015)

A Caprine Herpesvirus 1 Vaccine Adjuvanted with MF59™ Protects against Vaginal Infection and Interferes with the Establishment of Latency in Goats
por: Marinaro, Mariarosaria, et al.
Publicado: (2012)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

MF59(®)-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
por: Banzhoff, Angelika, et al.
Publicado: (2009)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Correction: MF59(®)-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
por: Banzhoff, Angelika, et al.
Publicado: (2009)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells
por: Cioncada, Rossella, et al.
Publicado: (2017)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
por: Li, Athena P. Y., et al.
Publicado: (2021)

Cost-Effectiveness of Vaccination of Older Adults with an MF59(®)-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
por: Jacob, Jorge, et al.
Publicado: (2023)

Timeline: Vaccines
por: Rappuoli, Rino
Publicado: (2020)

HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial
por: Colombatto, P, et al.
Publicado: (2014)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
por: Griffiths, Paul D, et al.
Publicado: (2011)

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59
por: Ren, Shu-Ting, et al.
Publicado: (2017)

A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis
por: Aghebati, Tamara, et al.
Publicado: (2016)

Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
por: Wijnans, Leonoor, et al.
Publicado: (2013)

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread
por: Gomes, A. C., et al.
Publicado: (2023)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with MF59-Adjuvanted H5 Vaccines Promotes Antibody Affinity Maturation towards the Hemagglutinin HA1 Domain and Broad H5N1 Cross-Clade Neutralization
por: Khurana, Surender, et al.
Publicado: (2014)

The immunology of SARS-CoV-2 infections and vaccines
por: Grigoryan, Lilit, et al.
Publicado: (2020)

Sustainable vaccine development: a vaccine manufacturer's perspective
por: Rappuoli, Rino, et al.
Publicado: (2018)

The challenge of developing universal vaccines
por: Rappuoli, Rino
Publicado: (2011)

Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
por: Baraniak, Ilona, et al.
Publicado: (2019)

Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study
por: Rubinstein, F, et al.
Publicado: (2013)

Novel vaccination strategies
por: Lattanzi, Maria, et al.
Publicado: (2005)

The safety of vaccines
por: O'Hagan, Derek T., et al.
Publicado: (2004)

Emerging concepts in the science of vaccine adjuvants
por: Pulendran, Bali, et al.
Publicado: (2021)

Vaccines, emerging viruses, and how to avoid disaster
por: Rappuoli, Rino
Publicado: (2014)

Age and Influenza-Specific Pre-Vaccination Antibodies Strongly Affect Influenza Vaccine Responses in the Icelandic Population whereas Disease and Medication Have Small Effects
por: Olafsdottir, Thorunn A., et al.
Publicado: (2018)

Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis
por: Yang, Jing, et al.
Publicado: (2020)

Editorial overview: Preventive and therapeutic vaccines: Vaccination against viral disease — current advances and challenges
por: Rappuoli, Rino, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gcrublrkpjeophvgcocesis3t0